The test, which the company plans to launch later this year, will use MALDI-based proteomics to assess patients' likelihood of responding to immunotherapies.
Progenetics will distribute GeneStrat and Veristrat liquid biopsy tests in Israel, making Biodesix's tests available in the Middle East for the first time.
The deal gives the firm access to Bioyong's network of hospital-installed mass specs on which it hopes to place assays including its Veristrat lung cancer test.
Studies presented at the recent SITC annual meeting indicate the company's MALDI-based proteomic tests could help guide checkpoint inhibitor treatment.
The company said Humana, Medical Mutual of Ohio, and PreferredOne will now cover the non-small cell lung cancer test for their 11.5 million members.
Recently presented studies support the utility of Genestrat and Veristrat for detecting actionable mutations and guiding therapy in drug-resistant lung cancer patients.
Clinical lab supply firm Streck will exclusively supply Biodesix with DNA and RNA tubes, including its lines of blood collection tubes.
Horizon BCBS of New Jersey, which covers 3.8 million people in that state, began covering the test for patients with non-small cell lung cancer on May 10, 2016.
BlueCross BlueShield of Florida began covering the test on March 15, and Health Care Services Corporation will begin coverage in June.
Norgen Biotek's sample prep products are already used in Biodesix's GeneStrat liquid biopsy assay workflow.
US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.
In Science this week: almond reference genome, and more.